Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGN9220 + odronextamab
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
REGN9220 + odronextamab is an investigational combination therapy consisting of REGN9220, a fully human bispecific monoclonal antibody targeting CD22 and 4-1BB (CD137), and odronextamab, a fully human bispecific monoclonal antibody targeting CD20 and CD3. Developed by Regeneron, this combination is designed to treat relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs), such as diffuse large B-cell lymphoma (DLBCL). REGN9220 acts as a costimulatory bispecific antibody that provides localized T-cell costimulation via 4-1BB specifically in the presence of CD22-expressing B-cells. This localized costimulation is designed to enhance the T-cell-mediated tumor-killing activity of the CD20 x CD3 T-cell engager odronextamab while minimizing systemic toxicity.
- Other names
- REGN-9220 + odronextamabREGN9220 + odronextamabREGN9220 and odronextamabREGN-9220 and odronextamabREGN 9220 and odronextamabodronextamab + REGN-9220odronextamab + REGN9220odronextamab and REGN9220
02
Targets
CD20 (B-lymphocyte antigen CD20)CD22 (Cluster of Differentiation 22)CD3 (T-cell surface glycoprotein CD3)TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on REGN9220 + odronextamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGN9220 + odronextamab.